At least 16 biotechs and pharmas are slated to report earnings this week. Two large-cap biotechs - Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and Gilead Sciences Inc. (NASDAQ:GILD) - are expected to report 2Q14 EPS growth of 47% or more on strong sales. Alexion markets Soliris eculizumab for rare blood disorders and is anticipated to post a 38% increase in 2Q14 revenues to $510 million. The Street expects Gilead, which launched HCV drug Sovaldi sofosbuvir last December